ASH 2022 | Prognostic value of the updated ICC and WHO classifications for MDS
Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the new World Health Organization (WHO) and International Consensus Classification (ICC) for myelodysplastic syndromes (MDS), and the results of a study assessing their prognostic value. These guidelines characterize MDS based on molecular events, including SF3B1, TP53, and del(5q). Dr Komrokji highlights that multivariate analysis indicated that TP53 mutation status was the strongest predictor of patient outcome, in addition to multilineage dysplasia, myeloblast percentage, fibrosis, and SF3B1. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Servier: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Speakers Bureau; Geron: Consultancy; Acceleron Pharma: Consultancy; CTI BioPharma, Innovent: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Taiho Oncology: Consultancy, Membership on an entity’s Board of Directors or advisory committees; PharmaEssentia, Takeda: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Jazz Pharmaceuticals: Consultancy, Honoraria, Speakers Bureau; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau.
